CALGARY, ALBERTA -- (MARKET WIRE) -- September 28, 2006 -- Resverlogix Corp. (“Resverlogix”) (TSX: RVX), is pleased to announce today that its first lead candidate RVX-208 has illustrated the ability to raise ApoA-I levels in animals up to 180% over controls. It is estimated that a larger than 8% permanent ApoA-I increase in humans would have a significant impact on atherosclerosis and cardiovascular disease. The Company has previously announced that it will commence first administration in microdosing human trials, early in 2007.
